Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Other Non Operating Income: 2022-2025

Historic Other Non Operating Income for ARS Pharmaceuticals (SPRY) over the last 4 years, with Sep 2025 value amounting to $2.0 million.

  • ARS Pharmaceuticals' Other Non Operating Income fell 22.10% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year decrease of 3.23%. This contributed to the annual value of $11.4 million for FY2024, which is 13.58% down from last year.
  • As of Q3 2025, ARS Pharmaceuticals' Other Non Operating Income stood at $2.0 million, which was down 25.27% from $2.7 million recorded in Q2 2025.
  • Over the past 5 years, ARS Pharmaceuticals' Other Non Operating Income peaked at $3.8 million during Q1 2023, and registered a low of -$151,000 during Q1 2022.
  • For the 3-year period, ARS Pharmaceuticals' Other Non Operating Income averaged around $3.0 million, with its median value being $3.0 million (2024).
  • Its Other Non Operating Income has fluctuated over the past 5 years, first soared by 6,521.28% in 2023, then declined by 22.71% in 2024.
  • ARS Pharmaceuticals' Other Non Operating Income (Quarterly) stood at $1.2 million in 2022, then surged by 164.99% to $3.1 million in 2023, then decreased by 1.08% to $3.0 million in 2024, then declined by 22.10% to $2.0 million in 2025.
  • Its Other Non Operating Income stands at $2.0 million for Q3 2025, versus $2.7 million for Q2 2025 and $3.2 million for Q1 2025.